ARO-MAPT-SC is an investigational antisense oligonucleotide (ASO) therapy developed by Arrowhead Pharmaceuticals designed to reduce production of microtubule-associated protein tau (MAPT) in early Alzheimer's disease. This Phase 1/2 trial (NCT07221344) represents a pioneering approach to neurodegenerative disease treatment by targeting tau at its source—the messenger RNA that encodes the tau protein—rather than targeting already-formed tau aggregates with antibodies.
The trial evaluates the safety, tolerability, and pharmacokinetics of ARO-MAPT-SC administered via intrathecal injection, marking one of the first clinical applications of RNA interference technology for Alzheimer's disease modification. If successful, this approach could establish a new therapeutic paradigm for tauopathies beyond traditional antibody-based approaches.
| Parameter |
Value |
| NCT Number |
NCT07221344 |
| Phase |
Phase 1/2 |
| Status |
Recruiting |
| Sponsor |
Arrowhead Pharmaceuticals |
| Intervention |
ARO-MAPT-SC (tau-targeted antisense oligonucleotide) |
| Estimated Enrollment |
60 participants |
| Study Start |
June 2022 |
| Estimated Completion |
December 2025 |
| Route |
Intrathecal (lumbar puncture) |
| Study Design |
Randomized, placebo-controlled, dose-escalation |
| Arm |
Intervention |
Dose |
Randomization |
| 1 |
ARO-MAPT-SC |
Low dose |
3:1 active:placebo |
| 2 |
ARO-MAPT-SC |
Medium dose |
3:1 active:placebo |
| 3 |
ARO-MAPT-SC |
High dose |
3:1 active:placebo |
| 4 |
Placebo |
N/A |
3:1 active:placebo |
The trial employs a single ascending dose (SAD) followed by multiple ascending dose (MAD) design to establish maximum tolerated dose.
ARO-MAPT-SC utilizes RNA interference to selectively reduce tau production:
ASO Mechanism:
- Target binding: ASO binds complementarily to MAPT mRNA
- RNase H recruitment: The RNA-DNA hybrid recruits RNase H enzyme
- mRNA degradation: RNase H cleaves the mRNA strand
- Translation block: Degraded mRNA cannot be translated into protein
- Tau reduction: All tau isoforms (3R, 4R, and 2N) are reduced
Targeted Approach:
- Direct targeting of tau at the production level
- Reduction of all tau isoforms simultaneously
- No effect on existing tau protein (cannot clear established tangles)
- Potential for disease modification if administered early enough
Arrowhead Pharmaceuticals employs its proprietary TRiP™ delivery platform:
Platform Features:
- Conjugate chemistry: Enables tissue-specific delivery
- Enhanced uptake: Improved cellular entry vs. naked ASOs
- Reduced off-target: Tissue-selective delivery reduces side effects
- Sustained effect: Long duration of gene silencing after dosing
ARO-MAPT-SC Specifics:
- Target: MAPT mRNA in neuronal cells
- Delivery: Conjugate enables uptake across blood-brain barrier when delivered intrathecally
- Duration: Effects persist for months after single dose
¶ Advantages Over Antibody Approaches
| Feature |
Antibody Therapy |
ASO Therapy (ARO-MAPT-SC) |
| Target |
Extracellular tau |
Intracellular tau mRNA |
| Mechanism |
Tau clearance |
Tau production reduction |
| Tau isoforms |
Limited by epitope |
All isoforms |
| Delivery |
Peripheral injection |
Intrathecal |
| Duration |
Frequent dosing |
Less frequent |
Tau protein plays a central role in Alzheimer's disease pathogenesis:
Tau Biology:
- Normal function: Stabilizes microtubules, supports axonal transport
- Hyperphosphorylation: Abnormal phosphorylation leads to aggregation
- NFT formation: Paired helical filaments accumulate as neurofibrillary tangles (NFTs)
- Spread: Pathologic tau propagates through neural networks
Clinical Correlation:
- Regional tau burden correlates with cognitive impairment
- NFT count at autopsy predicts ante-mortem dementia severity
- Tau accumulation precedes clinical symptoms
- Tau PET signal predicts future cognitive decline
Reducing tau production could provide disease-modifying benefits:
Theoretical Benefits:
- Prevent formation of new NFT pathology
- Slow or halt disease progression
- Potentially reverse cognitive decline if treatment begins early
- Address upstream cause rather than downstream effects
Preclinical Evidence:
- Tau reduction improves cognition in mouse models
- Tau ASOs reduce tau in brain and CSF of animal models
- Partial reduction sufficient for benefit (not complete elimination)
The trial follows a structured development approach:
- Cohorts: 3 dose levels
- Participants: 8-12 per cohort
- Randomization: 3:1 active:placebo
- Duration: 12-week observation per cohort
- Endpoints: Safety, PK, CSF tau biomarkers
- Cohorts: 3 dose levels
- Participants: 10-15 per cohort
- Dosing: Monthly intrathecal administration
- Duration: 6-month treatment + 6-month follow-up
- Endpoints: Safety, efficacy endpoints
- Age: 55-80 years
- Diagnosis: Early Alzheimer's disease (MCI due to AD or mild AD dementia)
- Cognitive status: MMSE 20-28
- Amyloid positive: Confirmed via PET or CSF biomarkers (Aβ42, p-tau)
- Stable medication: On stable AD medications for ≥30 days
- Capacity: Able to provide informed consent with study partner
- Neurological: History of stroke, seizures, or other neurodegenerative disease
- Psychiatric: Active major depression, psychosis
- Medical: Contraindications to lumbar puncture
- Prior therapy: Prior exposure to tau-targeted therapies
- Imaging: Significant cerebrovascular disease on MRI
Comprehensive screening includes:
- Informed consent: Detailed explanation of procedures and risks
- Medical history: Complete neurological and psychiatric history
- Physical examination: Including vital signs and neurological exam
- Cognitive assessment: MMSE, CDR, ADAS-Cog13, FCSRT
- Brain MRI: Structural imaging to rule out other pathology
- PET imaging: Amyloid PET (if available)
- CSF collection: Lumbar puncture for biomarker analysis
- Laboratory tests: Blood chemistry, hematology, urinalysis
Intrathecal Administration:
- Participant positioned for lumbar puncture
- CSF collected for baseline biomarkers (optional)
- ARO-MAPT-SC or placebo administered
- Post-injection monitoring (4-6 hours)
- Assessment of injection site
Safety Monitoring:
- Vital signs (BP, HR, temperature)
- Neurological assessments
- Injection site inspection
- Adverse event collection
| Timepoint |
Assessments |
| Week 1 |
Safety call |
| Week 2 |
PK/PD sampling |
| Week 4 |
Cognitive testing, safety |
| Week 8 |
CSF biomarkers (subset) |
| Week 12 |
Full assessment |
| Month 6 |
Safety and efficacy |
| Month 12 |
Long-term follow-up |
-
Safety and Tolerability
- Incidence of adverse events (AEs)
- Incidence of serious adverse events (SAEs)
- Assessment of injection site reactions
- Neurological examinations
-
Pharmacokinetics
- Plasma concentrations of ARO-MAPT-SC
- CSF concentrations (subset of participants)
- Population PK modeling
-
Target Engagement
- Change in CSF total tau
- Change in CSF phosphorylated tau (p-tau181)
- Correlation with dose level
-
Efficacy Signals
- Change from baseline in cognitive scales (ADAS-Cog13, MMSE)
- Clinical Dementia Rating (CDR) change
- Quality of life measures (QoL-AD)
-
Biomarker Assessments
- Tau PET imaging (optional substudy)
- Transcriptomic analysis of CSF cells
- Pharmacodynamic biomarkers
Key Preclinical Findings:
- Tau ASOs reduce brain tau in mouse models by >50%
- Reduction in tau protein in CSF of treated animals
- Improved cognitive performance in tau transgenic mice
- No significant off-target effects at therapeutic doses
- Toxicology studies in rodents and non-human primates
- No significant safety concerns at projected therapeutic doses
-剂量-limited毒性 identified in chronic toxicology studies
- Supportive IND-enabling studies completed
ARO-MAPT-SC represents Arrowhead's neurological portfolio expansion:
Company's CNS Pipeline:
- CNS-directed ASO programs for various targets
- Established intrathecal delivery capabilities
- Track record with other CNS programs
Lessons from Other ASOs:
- Nusinersen (Spinraza) for spinal muscular atrophy
- Inotersen (Tegsedi) for hATTR polyneuropathy
- These programs established safety of intrathecal ASO delivery
¶ Competitive Landscape
| Approach |
Agent |
Company |
Stage |
| ASO |
ARO-MAPT-SC |
Arrowhead |
Phase 1/2 |
| Antibody |
Semorinemab |
Roche |
Phase 2 |
| Antibody |
Gosuranemab |
Biogen |
Phase 2 |
| Antibody |
tilavonemab |
AbbVie |
Phase 2 |
| Vaccine |
AADvac1 |
Axon Neuroscience |
Phase 2 |
| Small molecule |
TRx0237 |
TauRx |
Phase 3 |
Unique Advantages:
- First ASO targeting tau in clinical development
- Targets tau production, not extracellular tau
- Potential for disease modification
- Single-agent approach vs. combination strategies
Challenges:
- Intrathecal delivery (invasive) vs. subcutaneous
- May not clear existing tau pathology
- Unproven in large clinical trials
- Long-term safety unknown
Based on other intrathecal ASO programs and preclinical data:
Common Expected:
- Headache (post-lumbar puncture)
- Back pain at injection site
- Mild CSF pleocytosis
- Transient elevations in CSF protein
Rare but Monitored:
- Infection (meningitis risk)
- Bleeding (spinal hematoma)
- Neurological deficits
- Hypersensitivity reactions
- Careful patient selection
- Strict sterility procedures
- Close neurological monitoring
- Regular safety assessments
Potential regulatory advantages:
- Fast Track designation: Possible based on unmet need
- Breakthrough designation: If significant efficacy signals
- Accelerated approval: Based on CSF biomarker endpoint
The trial may support biomarker-based accelerated approval:
- CSF tau reduction as surrogate endpoint
- Established biomarker assays available
- Regulatory precedent from other ASO programs
Phase 3 Planning:
- Larger confirmatory trials
- Earlier disease stages
- Combination approaches
- Other tauopathies: Progressive supranuclear palsy, corticobasal degeneration
- Prevention studies: Pre-symptomatic individuals
- Combination therapy: With anti-amyloid agents
Arrowhead Pharmaceuticals is a leader in RNA interference therapeutics:
Platform Technology:
- Targeted RNAi Polymers (TRiP™)
- Proprietary conjugates for tissue targeting
- Broad pipeline across therapeutic areas
Pipeline Focus:
- Liver diseases (most advanced)
- CNS disorders (growing)
- Oncology applications
- Cardio-metabolic diseases
Track Record:
- Multiple programs in clinical development
- Successful FDA approvals
- Strong intellectual property position